Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels et al

Ann Rheum Dis. 2019 Jul;78(7):e62. doi: 10.1136/annrheumdis-2018-213618. Epub 2018 May 18.

Authors

Leonieke J J van Mens¹, Marleen G H van de Sande¹, Arno W R van Kuijk², Dominique L P Baeten¹, Laura C Coates³

Affiliations

¹ Clinical Immunology and Rheumatology, Amsterdam Rheumatology and Immunology Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
² Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, The Netherlands.
³ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

PMID: 29776975
DOI: 10.1136/annrheumdis-2018-213618

No abstract available

Keywords: outcomes research; psoriatic arthritis; treatment.

Publication types

Letter
Comment

MeSH terms

Antirheumatic Agents*
Arthritis, Psoriatic*
Cohort Studies
Humans

Substances

Antirheumatic Agents

Grant support

CS-2016-16-016/DH_/Department of Health/United Kingdom